Dual antiplatelet therapy following percutaneous coronary intervention: clinical and economic impact of standard versus extended duration

Wells GA, Elliott J, Kelly S, Bai Z, Boucher M, Skidmore B, So D, Laplante S, Lee K
Record ID 32018002221
Authors' objectives: This project evaluated the clinical and economic effectiveness of extending dual antiplatelet therapy, or DAPT (i.e., a combination of ASA and a P2Y12 inhibitor), following percutaneous coronary intervention (PCI). This project aimed to answer the following policy questions: Policy Question 1: Should P2Y12 inhibitors (i.e., clopidogrel, prasugrel, or ticagrelor) be reimbursed for use beyond 12 months in combination with ASA for patients who recently underwent PCI with bare-metal stent (BMS) or drug-eluting stent (DES) insertion? Policy Question 2: Which of the P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) should be reimbursed for use beyond 12 months in combination with ASA for patients who underwent PCI with BMS or DES insertion? A recommendations report was also produced. This report includes recommendations for the optimal use of DAPT in terms of duration of clinical utilization and reimbursement. Recommendations were based on findings from the science report, as well as stakeholder feedback.
Project Status: Completed
Year Published: 2019
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
Pubmed ID: 31246386
MeSH Terms
  • Dual Anti-Platelet Therapy
  • Coronary Artery Disease
  • Drug-Eluting Stents
  • Stents
  • Drug Administration Schedule
  • Duration of Therapy
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors
  • Costs and Cost Analysis
  • Clopidogrel
  • Prasugrel Hydrochloride
  • Ticagrelor
  • Dual antiplatelet therapy
  • Clopidogrel
  • Prasugrel
  • Ticagrelor
  • Duration of therapy
  • Percutaneous coronary interventions
  • Stents
  • Acetylsalicylic acid
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca

Canadian Agency for Drugs and Technologies in Health (CADTH)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.